EPM is a patient-focused Pharmaceutical group.
EPM develops prescription medicine derived from synthetic cannabinoid acids to address unmet patient needs.
Our mission is to develop safer treatment options for people.
Our focus is to bring cannabinoid acid based medicines to patients in a wide range of therapeutic conditions, current treatment developments include Psoriasis, IBD and ARDS. At EPM we care to make a real difference by helping people live a life of higher quality.
EPM created a pipeline which includes the discovery of 14 protected synthetic molecules, including 8 novel structures and the development of various processes.
EPM maintains control over all aspects of the product development process – research and discovery, formulation, toxicology, scaleup manufacturing, clinical trial and regulatory affairs.
EPM is leading the way in realizing the untapped potential of cannabinoids acids as new pharmaceutical treatments.